Coffee as hepatoprotective factor
Authors:
Mária Szántová; Zuzana Ďurkovičová
Authors‘ workplace:
III. interná klinika LF UK a UN, Nemocnica akademika Ladislava Dérera, Bratislava, Slovenská republika
Published in:
Vnitř Lék 2016; 62(12): 990-997
Category:
Reviews
Práca bola prezentovaná formou prednášky na 44. májových hepatologických dňoch 19.–21. 5. 2016, Donovaly, Slovenská republika.
Overview
The mind about the coffee did change upon the recent studies and metaanalysis of the last years. Consensual protective effect of coffee on the progression of chronic liver diseases (NASH, viral hepatitis, liver cirrhosis, hepatocelullar carcinoma) was detected in experimental, clinical and large population studies together with decrease of mortality. Antioxidant, antifibrotic, insulinsensitizing and anticarcinogenic effect of coffee were detected. Modulation of genetic expression of key enzymes of fatty acid synthesis, modulation of mRNA included in autophagia, reduction of stress of endoplasmatic reticulum together with decrease of proinflammatory cytokines and decrease of fibrogenesis are main mechanisms. Chlorogenic acids, diterpens (cafestol, kahweol), caffein, polyfenols and melanoidins are key protective components of coffee. Inverse dose-dependent correlation of coffee consumption with liver diseases was found in clinical and population studies. Coffee is non-pharmacological tool of primary and secondary prevention of chronic liver diseases. Review of published data together with supposed mechanisms of hepatoprotection are given.
Key words:
coffee – hepatoprotective effect – metaanalysis
Sources
1. Szántová M. Aktuálny diagnostický prístup k cirhóze a portálnej hypertenzii 1: Rizikové faktory cirhózy – dá a má sa u jedinca cirhóza predpokladať a cielene hľadať? Gastroenterol Prax 2015; 14(1): 10–17.
2. Rehm J, Zatonksi W, Taylor B et al. Epidemiology and alcohol policy in Europe. Addiction 2011; 106(Suppl 1): S11-S19.
3. Nilssen O, Forde OH. Seven-year longitudinal population study of change in gamma-glutamyltransferase: the Tromso Study. Am J Epidemiol 1994; 139(8): 787–792.
4. Tanaka T, Tokunaga S, Kono S et al. Coffee consumption and decreased serum gamma-glutamytransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol 1998; 27(3): 438–443.
5. Casiglia E, Spolaore P, Ginocchio G et al. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol 1993; 9(3): 293–297.
6. Ikeda M, Maki T, Yin G et al. Relation of coffee consumption and serum liver enzymes in Japanese men and women with reference to effect modification of alcohol use and body mass index. Scand J Clin Lab Invest 2010; 70(3): 171–179. Dostupné z DOI: <http://dx.doi.org/10.3109/00365511003650165>.
7. Pham NM, Nanri A, Yasuda K et al. Habitual consumption of coffee and green tea in relation to serum adipokines: a cross-sectional study. Eur J Nutr 2015; 54(2): 205–214. Dostupné z DOI: <http://dx.doi.org/10.1007/s00394–014–0701–4>.
8. Imatoh T, Tanihara S, Miyazaki M et al. Coffee consumption but not green tea consumption is associated with adiponectin levels in Japanese males. Eur J Nutr 2011; 50(4): 279–284. Dostupné z DOI: <http://dx.doi.org/10.1007/s00394–010–0136–5>.
9. Ding Q, White SP, Ling C et al. Resistin and cardiovascular disease. Trends Cardiovasc Med 2011; 21(1): 20–27. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tcm.2012.01.004.
10. Zheng X, Dai W, Chen X et al. Caffeine reduces hepatic lipid accumulation through regulation of lipogenesis and ER stress in zebrafish larvae. J Biomed Sci 2015; 22:105. Dostupné z DOI: 11. Modi AA, Feld JJ, Park Y et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010; 51(1): 201–209. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.23279>.
12. Kempf K, Herder C, Erlung I et al. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr 2010; 91(4): 950–957. Dostupné z DOI: <http://dx.doi.org/10.3945/ajcn.2009.28548>.
13. Dranoff JA, Feld JJ, Lavoie EG et al. How does coffee prevent liver fibrosis? Biological plausability for recent epidemiological observations. Hepatology 2014; 60(2): 464–467. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.27032>.
14. Vitaglione P, Morisco F, Mazzone G et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology 2010; 52(5): 1652–1661. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.23902>.
15. Arauz J, Moreno MG, Cortes-Reynosa P et al. Coffee atenuates fibrosis by decreasing the expression of TGF- and CTGF in a murine model of liver damage. J Appl Toxicol 2013; 33(9): 970–979. Dostupné z DOI: <http://dx.doi.org/10.1002/jat.2788>.
16. Daly JW. Caffeine analogs: biomedical impact. Cell Mol Life Sci 2007; 64(16): 2153–2169.
17. Molloy JW, Calcagno CH J, Williams CH D et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012; 55(2): 429–436. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.24731>.
18. Shen H, Rodriguez AC, Shiani A et al. Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and metaanalysis. Ther Adv Gastroenterol 2016; 9(1): 113–120. Dostupné z DOI: <http://dx.doi.org/10.1177/1756283X15593700>.
19. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010; 7(8): 425–436. Dostupné z DOI: <http://dx.doi.org/10.1038/nrgastro.2010.97>.
20. Ong A, Wong VW, Wong GI et al. The effect of caffeine and alcohol consumption on liver fibrosis- a study of 1045 Asian hepatitis B patients using transient elastography. Liver Int 2011; 31(7): 1047–1053. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1478–3231.2011.02555.x>.
21. Leung WW, Ho SC, Chan HL et al. Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case control study. J Epidemiol Community Health 2011; 65(6): 556–558. Dostupné z DOI: <http://dx.doi.org/10.1136/jech.2009.104125>.
22. Klatsky AL, Morton C, Udaltsova N et al. Coffee, cirrhosis and transaminase enzymes. Arch Intern Med 2006; 166(11): 1190–1195.
23. Klatsky AL, Armstrong MA, Friedman GD. Alcohol, smoking, coffee and cirrhosis. Am J Epidemiol 1992; 136(10):1248–1257.
24. Goh GB, Chow WCH, Wang R et al. Coffee, alcohol and other beverages in relation to cirrhosis mortality: The Singapore Chinese Health Study. Hepatology 2014; 60(2): 661–669. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.27054>.
25. Jiang X, Zhang D, Jiang W. Coffee and caffeine intake and incidence of type 2 diabetes mellitus: a metaanalysis of prospective studies. Eur J Nutr 2014; 53(1): 25–38. Dostupné z DOI: <http://dx.doi.org/10.1007/s00394–013–0603-x>.
26. Wu T, Willett WC, Hankinson SE et al. Caffeinated coffee, decaffeinated coffee and caffeine in relation to plasma C-peptide levels, a marker of insulin secretion, in US women. Diabetes Care 2005; 28(6): 1390–1396.
27. Greenberg JA, Owen DR, Geliebter A. Decaffeinated coffee and glucose metabolism in young men. Diabetes Care 2010; 33(2)2: 278–280. Dostupné z DOI: <http://dx.doi.org/10.2337/dc09–1539>.
28. Loopstra-Masters RC, Liese AD, Haffner SM et al. Associations between the intake of caffeinated and decaffeinated coffee and measures of insulin sensitivity and beta cell function. Diabetologia 2011; 54(2): 320–328. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–010–1957–8>.
29. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: A meta-analysis. Gastroenterology 2007; 132(5): 1740–1745.
30. Hu G, Tuomilehto J, Pukkala E et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 2008; 48(1): 129–136. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.22320>.
31. Inoue M, Yoshimi I, Sobue T et al. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: A prospective study in Japan. J Natl Cancer Inst 2005; 97(4): 293–300.
32. Sang LX, Chang B, Li X-H et al. Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. BMC Gastroenterology 2013; 13: 34. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–230X-13–34>.
33. Bravi F, Bosetti C, Tavani A et al. Coffee reduces risk for hepatocellular carcinoma: an update metaanalysis. Clin Gastroenterol Hepatol 2013; 11(11): 1413–1421. e1. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2013.04.039>.
34. World Cancer Research Fund International. CUP panel. Dostupné z WWW: Dostupné z DOI: <http://www.wcrf.org/sites/default/files/Liver-Cancer-2015-Report.pdf>.
35. Aleksandrova K, Bamia CH, Drogan D et al. The Association of coffee intake with liver cancer risk is mediated bybiomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2015; 102(6): 1498–1508. Dostupné z DOI: <http://dx.doi.org/10.3945/ajcn.115.116095>.
36. Freedman ND, Park Y, Abnet CC et al. Association of coffee drinking with total and cause-specific mortality. N Engl J Med 2012; 366(20): 1891–1904. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1112010>.
37. Saab S, Mallam D, Cox GA et al. Impact of coffee on liver diseases. Liver International 2014; 34(4): 495–504. <http://dx.doi.org/10.1111/liv.12304>.
38. Tverdal A, Skurtveit S. Coffee intake and mortality from liver cirrhosis. Ann Epidemiol 2003; 13(6): 419–423.
39. Schwartz JM, Reinus JF. Prevalence and natural history of alcoholic liver disease. Clin Liver Dis 2012; 16(4): 659–666. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cld.2012.08.001>.
40. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34(3): 274–285. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2036.2011.04724.x>.
41. Muriel P, Arauz J. Coffee and liver diseases. Fitoterapia 2010; 81(5): 297–305. Dostupné z DOI: <http://dx.doi.org/10.1016/j.fitote.2009.10.003>.
42. Viana ALM, Fonseca MDM, Meireles ELJ et al. Effects of the consumption of caffeinated and decaffeinated instant cofee beverages on oxidative stress induced by strenuous exercise in rats. Plant Foods Hum Nut.r 2012; 67(1): 82–87. Dostupné z DOI: <http://dx.doi.org/10.1007/s11130–011–0267–8>
43. Feng R, Lu Y, Bowman LL et al. Inhibition of activator protein-1 NF-kappaB and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem 2005; 280(30): 27888–27895.
44. Kalthoff S, Ehmer U, Freiberg N et al. Coffee induces expression of glucuronyltransferases via the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology 2010; 139(5): 1699–1710, 1710.e1–2. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2010.06.048>.
45. Wedick NM, Brennan AM, Sun Q et al. Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. Nutr J 2011; 10: 93. Dostupné z DOI: <http://dx.doi.org/10.1186/1475–2891–10–93>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2016 Issue 12
Most read in this issue
- Thrombophilia
- Oral antidiabetic drugs in treatment of type 1 diabetes mellitus
- Coffee as hepatoprotective factor
- Takotsubo cardiomyopathy: incidence, etiology, complications, therapy and prognosis